Human nsclc cell lines

Manufactured by American Type Culture Collection

Sourced in United States

The American Type Culture Collection (ATCC) offers a range of human non-small cell lung cancer (NSCLC) cell lines. These cell lines are derived from various types of NSCLC, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The cell lines are authenticated and undergo regular quality control testing to ensure their integrity and consistency.

Automatically generated - may contain errors

Lab products found in correlation

Rpmi 1640, by Merck Group (2 mentions) Atezolizumab, by Selleck Chemicals (2 mentions) Foetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Phospho mapk44 42, by Cell Signaling Technology (1 mentions) Mapk44 42, by Cell Signaling Technology (1 mentions) Monoclonal anti α tubulin antibody, by Merck Group (1 mentions) Rabbit anti mouse igg, by Merck Group (1 mentions) Goat anti rabbit igg, by Merck Group (1 mentions) Mhc 1, by Cell Signaling Technology (1 mentions) Ctla4, by Cell Signaling Technology (1 mentions) Pd l1, by Cell Signaling Technology (1 mentions) Mycoplasma pcr reagent set, by Euroclone (1 mentions) Ficoll paque plus, by GE Healthcare (1 mentions) Cetuximab, by Selleck Chemicals (1 mentions) Short tandem repeat profiling, by Promega (1 mentions) Avelumab, by Merck Group (1 mentions) Egm 2 medium, by Merck Group (1 mentions) Lipofectamine 3000, by Thermo Fisher Scientific (1 mentions) Mir nc, by Thermo Fisher Scientific (1 mentions) Ro 3306, by Merck Group (1 mentions)

Spelling variants of this product

NSCLC cell lines (9 citations)

5 protocols using human nsclc cell lines

NSCLC Cell Line Cultivation and Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human NSCLC cell lines were obtained by the American Type Culture Collection (ATCC, Manassas, Virginia, USA) and were cultured in RPMI-1640 (Sigma-Aldrich) medium which was supplemented with 10% foetal bovine serum (FBS; Life Technologies, Gaithersburg, Maryland, USA) in a humidified atmosphere with 5% CO₂. The identity of cell lines was confirmed by human STR testing (ATCC). Selumetinib (MEK-I, AZD6244) and atezolizumab were purchased from Selleck Chemicals, Munich, Germany. Epacadostat was provided by Incyte Biosciences International S.a.r.l.
Primary antibodies for western blot analysis against phospho-MEK, MEK, phospho-MAPK44/42, MAPK44/42, PD-L1, Ido-1, CTLA4, LAG-3, TIM-3 and MHC-I were obtained from Cell Signaling Technology; the following secondary antibodies from Bio-Rad were used: goat anti-rabbit IgG, rabbit anti-mouse IgG and monoclonal anti-α tubulin antibody from Sigma Chemical Co.

Della Corte C.M., Ciaramella V., Ramkumar K., Vicidomini G., Fiorelli A., Nardone V., Cappabianca S., Cozzolino I., Zito Marino F., Di Guida G., Wang Q., Cardnell R., Gay C.M., Ciardiello D., Martinelli E., Troiani T., Martini G., Napolitano S., Wang J., Byers L.A., Ciardiello F, & Morgillo F. (2022). Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. Journal of Translational Medicine, 20, 541.

+ Open protocol

+ Expand

Characterization of NSCLC Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human NSCLC cell lines were purchased from American Type Culture Collection, and cultured in RPMI 1640 Medium, supplemented with 10% fetal bovine serum (FBS), 1% (vol/vol) penicillin-streptomycin antibiotics and 1% (vol/vol) L-glutamine. Cell lines were grown at 37°C. All cell lines were routinely tested for Mycoplasma (Mycoplasma PCR Reagent set, Euroclone) and authenticated by short tandem repeat (STR) profiling (BMR Genomics, Italy). Mutational status of NSCLC cell lines is reported in online supplemental table 1.

Trono P., Tocci A., Palermo B., Di Carlo A., D'Ambrosio L., D'Andrea D., Di Modugno F., De Nicola F., Goeman F., Corleone G., Warren S., Paolini F., Panetta M., Sperduti I., Baldari S., Visca P., Carpano S., Cappuzzo F., Russo V., Tripodo C., Zucali P., Gregorc V., Marchesi F, & Nistico P. (2023). hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC. Journal for Immunotherapy of Cancer, 11(8), e006913.

+ Open protocol

+ Expand

Isolation and Culture of NSCLC Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human NSCLC cell lines were obtained by the American Type Culture Collection (ATCC, Manassas, Virginia, USA) and were cultured in RPMI-1640 (Sigma-Aldrich) medium which was supplemented with 10% foetal bovine serum (FBS; Life Technologies, Gaithersburg, Maryland, USA) in a humidified atmosphere with 5% CO₂. The identity of cell lines was confirmed by Short tandem repeat profiling (Promega). Cetuximab, atezolizumab and panitumumab were purchased from Selleck Chemicals (Munich, Germany). Avelumab, was provided by Merck (Darmstadt, Germany), as part of a Cooperative Research and Development Agreement. Peripheral blood mononuclear cells (PBMCs) from healthy donors (HD) or from NSCLC patients were isolated by Ficoll-Paque Plus (GE Healthcare). NK cells were obtained through magnetic separation by using the NK CELL isolation kit, HUMAN (Miltenyi Biotech 130-092-657) according to the manufacturer’s protocol.

Fasano M., Della Corte C.M., Di Liello R., Barra G., Sparano F., Viscardi G., Iacovino M.L., Paragliola F., Famiglietti V., Ciaramella V., Cimmino F., Capasso M., Iolascon A., Sforza V., Morabito A., Maiello E., Ciardiello F, & Morgillo F. (2020). Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. ESMO Open, 5(5), e000753.

+ Open protocol

+ Expand

Synthesis and Evaluation of SKLB-178 against NSCLC

Check if the same lab product or an alternative is used in the 5 most similar protocols

SKLB-178 (Figure 1A) was synthesized at the State Key Laboratory of Biotherapy, Sichuan University (details for the synthesis of SKLB-178 see Supporting Material). Gefitinib, Afatinib, Vandetanib, and Sorafenib were obtained from commercial source. All of the compounds were dissolved in dimethyl sulfoxide (DMSO), and the final concentration of DMSO in the incubation mixture did not exceed 0.1% (v/v) in each experiment in vitro. Human NSCLC cell lines were obtained from American Type Culture Collection (ATCC, Rockville, MD) and National Platform of Experimental Cell Resources for Sci-Tech (China). All tumor cell lines were cultured according to standard procedures and passaged for less than 6 months after receipt for resuscitation. Human umbilical vein endothelial cell (HUVEC) was isolated from human umbilical cord veins and grown in EGM-2 medium (Millipore, USA). HUVECs at passage 2–6 were used for all studies.

Zhong L., Yang J., Cao Z., Chen X., Hu Y., Li L, & Yang S. (2017). Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer. Oncotarget, 8(8), 12843-12854.

+ Open protocol

+ Expand

Investigating KRAS Mutant NSCLC Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

All the human NSCLC cell lines were purchased from American Type Culture Collection (ATCC). A549, CALU-1, and HCC827 cells were grown in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM l-glutamine, and 100 U/ml penicillin/streptomycin [19 ]. For primary cell-culture experiments, human lung biopsies were obtained from Azienda Ospedaliera Universitaria, Università degli Studi della Campania, Naples, Italy, and processed as indicated elsewhere [20 (link)]. For transient transfection of miRNAs, cells were seeded in 6-well plates one day ahead, grown to 50–70% confluence, and then transfected with 100 nM (final concentration) of pre-miR-34c-3p, pre-miR-negative control #1 (miR-NC), anti-miR-34c-3p, or anti-miR-NC (Ambion®, ThermoFisher Scientific, Milan, Italy), and 1 µg of KRAS^G12V (KRAS^mut) plasmid (a kind gift of Prof. Gabriella De Vita, University of Naples Federico II) using Lipofectamine 3000 (ThermoFisher Scientific, Milan, Italy), according to the manufacturer’s protocol. RO3306 was purchased by Sigma Aldrich (Milan, Italy) and used at final concentration of 9 μM.

Palma F., Affinito A., Nuzzo S., Roscigno G., Scognamiglio I., Ingenito F., Martinez L., Franzese M., Zanfardino M., Soricelli A., Fiorelli A., Condorelli G, & Quintavalle C. (2020). miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer. Cancer Gene Therapy, 28(5), 413-426.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!